ERBB2 and breast carcinoma: The mechanisms which contribute to LRIG1 downregulation in breast cancer are not fully understood but are known to include ERBB2-mediated repression [14] and loss of gene copy number, which conveys persistent risk of relapse in patients typically considered low-risk [15].